Breaking Biotech (@BreakingBioMatt) header
Breaking Biotech (@BreakingBioMatt) profile picture

Biotech investor/trader - Host of Breaking Biotech https://teapaw.org/t.co/P6wtEkED8z [email protected]

San Diego, CA
Joined September 2017
Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)Photo by Breaking Biotech (@BreakingBioMatt)
Going to go live in the 1 o'clock hour PST. Talking about $beam, $mrk and $rvmd
1
8
633
I'm starting a $RVMD position here
1
12
1,255
Going to go live in a couple hours, talking about $RYTM $RVMD and $MRNA
7
844
$TXG reporting basically flat YoY growth in Q3. Guiding 5% revenue growth 2026 over 2025, yet still trading at 12X multiple At least $TWST is guiding >20% rev growth
1
414
Nice to see another deal $RYTM! Feels like an expensive acquisition given the size of HO, but they must be confident about the potential in other MC4R-related obesity indications
1
2
828
Seems like an overreaction on a pretty positive ER $MDGL
4
817
$NAUT Q3 earnings: - $0.2M revenue (only 26K of that from services) - No ATM use in Q3 - Net loss: ~$16M - Cash $114M Will have to listen to the call to see if they have any more placements, but looks like another quarter without much adoption
3
4
1,635
After listening to the call, a couple of points stand out: - They refused to share details on early access customers/placements (fair to assume they haven't added anymore) - They haven't gotten buy-in from academics to submit S-10 grants (i.e. unlikely to have any academic instrument revenue until well into 2028) Seems like the company has big plans, but is still slow to execute with no sign that things are going to change. This should be trading below cash imo. Will see how the rest of the week plays out before considering more shorts.
1
221
Covering $NAUT, can't complain for a quick trade
1
8
1,970
The ignorance in this post is beyond the pale. I'm not even a mass spec expert, but to say that because a phosphate group adds the same mass no matter the position, means that MS cannot identify it is ridiculous. In bottom up proteomics, trypsin digests the full-length protein into often predictable size peptides before going through LC-MS/MS. p217 Tau for instance is found in a well-characterized 10 amino acid peptide after trypsin digestion, which allows distinguishing of it and other phospho-sites on Tau because of the predictable mass for that specific peptide. $NAUT does potentially have an advantage when it comes to understanding multiple phospho-sites on the same protein, but would be better to see the data in an independent lab. Here's 2 open access resources of the many many many peer reviewed pubs that are out there: nature.com/articles/s43587-0… link.springer.com/article/10…
I believe $NAUT is worth several billion today, because it's on a path to enable us to cure deadly diseases like Alzheimer's with a single prompt by 2027-2028. The breakthrough is not better protein measurement. It is reading the state machine of human biology. In Nautilus' tau paper, they found that phosphorylation is not random. pT181 makes pT217 about 8x more likely to appear on the same intact tau molecule. That matters because adding PO4 groups changes tau's charge distribution, which changes its conformation, which changes how tau binds microtubules. Microtubules are the rails neurons use to move mitochondria, vesicles and proteins over enormous distances. Tau helps stabilize those rails. Change tau's molecular configuration enough and: tau detaches → microtubules destabilize → transport breaks → neurons degenerate Alzheimer's may therefore not be "too much phosphorylated tau." It may be a progression through specific molecular states: tau A → pT181 → pT217 → additional PTMs → pathological proteoform And until now we largely could not read that combinatorial layer cleanly. Mass spectrometry measures mass and charge extremely well, but two intact tau molecules can have the same mass while carrying the same phosphate at different positions. Same atoms. Same mass. Very different biological behavior. Fragmentation can help, but reconstructing the exact PTM configuration of millions of intact molecules becomes difficult. Nautilus instead repeatedly interrogates the same intact protein with different probes. Its tau assay currently reads isoform plus 7 phosphorylation sites, creating hundreds of potential molecular states, while reporting about 5.5% end to end CV versus about 25% cited by management as an industry benchmark. And here is where this gets insane. Biology does not appear to occupy every theoretically possible state. Of 768 tau proteoforms their assay could resolve, they observed only 130 across all samples, and far fewer within individual biological systems. That means the real state space may be highly constrained. Now collect enough longitudinal data: initial proteomic state + treatment → final proteomic state Do that across millions of patients and interventions and AI stops being merely descriptive. It becomes predictive. Given molecular state X, what intervention moves the system toward healthy state Y? That is effectively a biological key:lock search problem. For tau alone, that could mean finding the intervention that prevents the proteoform trajectory that causes tau to abandon and damage the neuronal microtubule system. But tau is just one vertical assay. Add alpha synuclein. Amyloid beta. Cancer proteins. Immune proteins. Metabolic proteins. Thousands more. Eventually: genome + proteoform state + treatment history → full body molecular state transition model A genuine digital twin of human biology. The endgame is not simply detecting disease earlier. It is asking: given this person's current molecular state, what intervention moves them back toward the healthy state? And having an AI trained on billions of measured biological transitions produce the answer. That is why I think $NAUT is building something much larger than a proteomics machine. It is building the data layer required for AI to learn how to steer human biology.
2
1
3
557
I'm buying $IVA here, also starting a small $NAUT short. Earnings next week should reality-check $NAUT's commercial progress, trading over 4X cash with zero meaningful adoption of their platform
3
1,054